CASI PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.42 USD | +5.22% |
|
+7.56% | -66.20% |
| Mar. 28 | CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 05 | Top Midday Gainers | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 297.7 | 365.6 | 111.8 | 24.35 | 95.38 | 31.43 | - | - |
| Enterprise Value (EV) 1 | 243.5 | 299.3 | 111.8 | 24.35 | 95.38 | 31.43 | 31.43 | 31.43 |
| P/E ratio | -6.44 x | -6.7 x | -2.96 x | -0.59 x | -3.54 x | - | 7.12 x | 3.51 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 72.1 x | 24.1 x | 3.71 x | 0.56 x | 2.82 x | 0.53 x | 0.36 x | 0.27 x |
| EV / Revenue | 72.1 x | 24.1 x | 3.71 x | 0.56 x | 2.82 x | 0.53 x | 0.36 x | 0.27 x |
| EV / EBITDA | -9,234,771 x | -11,520,029 x | - | - | - | - | - | - |
| EV / FCF | - | - | -3,125,101 x | -912,171 x | - | - | - | - |
| FCF Yield | - | - | -0% | -0% | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 9,635 | 12,394 | 13,980 | 13,606 | 13,322 | 12,989 | - | - |
| Reference price 2 | 30.90 | 29.50 | 8.000 | 1.790 | 7.160 | 2.420 | 2.420 | 2.420 |
| Announcement Date | 3/16/20 | 3/30/21 | 3/28/22 | 4/26/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.131 | 15.14 | 30.17 | 43.11 | 33.88 | 59.17 | 88.09 | 118 |
| EBITDA | -32.24 | -31.74 | - | - | - | - | - | - |
| EBIT 1 | -39.99 | -33.7 | -41.84 | -34.03 | -25.08 | 0.049 | 14.84 | 30.61 |
| Operating Margin | -968.07% | -222.56% | -138.68% | -78.95% | -74.03% | 0.08% | 16.85% | 25.93% |
| Earnings before Tax (EBT) 1 | -45.36 | -47.51 | -35.84 | -37.43 | -26.29 | 0.049 | 14.84 | 30.61 |
| Net income 1 | -46.03 | -48.29 | -36.65 | -41.01 | -26.96 | 0.037 | 11.13 | 22.96 |
| Net margin | -1,114.31% | -318.92% | -121.5% | -95.14% | -79.58% | 0.06% | 12.63% | 19.45% |
| EPS 2 | -4.800 | -4.400 | -2.700 | -3.010 | -2.020 | - | 0.3400 | 0.6900 |
| Free Cash Flow | - | - | -35.79 | -26.7 | - | - | - | - |
| FCF margin | - | - | -118.63% | -61.94% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/20 | 3/30/21 | 3/28/22 | 4/26/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 8.112 | 9.158 | 9.062 | 8.573 | 10.21 | 15.26 | 8.347 | 9.82 | 8.838 | 6.874 | 12 | 13.8 | 15.5 | 17.8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | -6.892 | -11.44 | -7.29 | -7.746 | -6.354 | -12.64 | - | -9.345 | -5.095 | -3.427 | - | - | - | - |
| Operating Margin | -84.96% | -124.86% | -80.45% | -90.35% | -62.21% | -82.85% | - | -95.16% | -57.65% | -49.85% | - | - | - | - |
| Earnings before Tax (EBT) | -10.02 | -4.789 | -8.4 | -7.493 | -5.023 | -16.52 | - | -10.06 | -4.451 | -5.972 | - | - | - | - |
| Net income | -10.22 | -5.601 | -8.596 | -7.68 | -5.201 | -19.54 | - | -10.24 | -4.635 | -6.077 | - | - | - | - |
| Net margin | -126.04% | -61.16% | -94.86% | -89.58% | -50.93% | -128.04% | - | -104.27% | -52.44% | -88.41% | - | - | - | - |
| EPS 2 | -0.7000 | -0.4000 | -0.6000 | -0.5600 | -0.3800 | -1.440 | -0.4500 | -0.7700 | -0.3500 | -0.4600 | -0.0500 | -0.0100 | 0.0100 | 0.0300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/12/21 | 3/28/22 | 5/12/22 | 8/12/22 | 11/14/22 | 4/26/23 | 5/17/23 | 8/11/23 | 11/14/23 | 3/28/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 54.2 | 66.4 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | -35.8 | -26.7 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 0.43 | 1.5 | 8.95 | 5.61 | - | - | - | - |
| Capex / Sales | 10.34% | 9.9% | 29.65% | 13.02% | - | - | - | - |
| Announcement Date | 3/16/20 | 3/30/21 | 3/28/22 | 4/26/23 | 3/28/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.42
USD
Average target price
12
USD
Spread / Average Target
+395.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -66.20% | 31.43M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- CASI Stock
- Financials CASI Pharmaceuticals, Inc.
